Log in to search using one of your social media accounts:

 

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Media News - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news

HBV Infection and Development of Non-hodgkin Lymphoma HBV Infection and Development of Non-hodgkin Lymphoma
This study investigated the association of HBV infection and risk of non-Hodgkin's lymphoma. Might HBV vaccination reduce the risk in certain populations?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Glyphosate Exposure Causes Non-Hodgkin Lymphoma, Plaintiffs Say
SAN FRANCISCO - The plaintiffs in the multidistrict litigation for the herbicide Roundup on Oct. 27 filed a brief in California federal court, contending that there is "overwhelming evidence - whether it be the epidemiology, toxicology, or mechanistic data - that exposure to glyphosate-based formulations (GBFs) causes" non-Hodgkin lymphoma (NHL) (In re: Roundup Products Liability Litigation, No. 2741 MDL, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - November 8, 2017 Category: Medical Law Source Type: news

New treatment for adults with mantle cell lymphoma approved
The U.S. Food and Drug Administration today approved a new treatment for adult patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 31, 2017 Category: Consumer Health News Source Type: news

AstraZeneca wins US approval for lymphoma drug
U.S. regulators have approved a new treatment for patients with a rare form of non-Hodgkin lymphoma (Source: ABC News: Health)
Source: ABC News: Health - October 31, 2017 Category: Consumer Health News Tags: Health Source Type: news

Calquence Approved for Mantle Cell Lymphoma
TUESDAY, Oct. 31, 2017 -- Calquence (acalabrutinib) has been approved by the U.S. Food and Drug Administration to treat adults with mantle cell lymphoma. Mantle cell is an aggressive, fast-growing non-Hodgkin lymphoma, a cancer of the lymph system.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 31, 2017 Category: General Medicine Source Type: news

Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma
ROCHESTER, Minn. ? Mayo Clinic announced today that its Rochester campus is one of 16 cancer centers nationally selected to provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with?B-cell non-Hodgkin lymphoma?who have not responded to, or have relapsed, after two or more lines of treatment. The therapy, called axicabtagene ciloleucel (Yescarta), is [...] (Source: Mayo Clinic Business News)
Source: Mayo Clinic Business News - October 31, 2017 Category: Pharmaceuticals Source Type: news

Groundbreaking new cancer treatment approved
A second version of a new cancer treatment that uses a patient's own cells to fight non-Hodgkin's lymphoma has been approved by the FDA. Now 15,000 people may be eligible for the treatment. Dr. Tara Narula reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 23, 2017 Category: Consumer Health News Source Type: news

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). (Source: World Pharma News)
Source: World Pharma News - October 20, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Kite wins FDA approval for first adult CAR-T cell therapy
More than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults. The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two other treatments. Get the full story at our sister site, Drug Delivery Business News. The post Kite wins FDA approval for first adult CAR-T cell therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Oncology Regulatory/Compliance Wall Street Beat Gilead Sciences kitepharma Source Type: news

FDA Approves Gene Therapy Tested In Boston To Treat Adults With Lymphoma
TRENTON, N.J. (CBS/AP) — U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults. The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. That Novartis treatment was tested in Boston. In those tests, Dana Farber and Brigham and Women’s Hospital cancer researchers found that 80 percent of lymphoma patients who underwent the treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 19, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News blood cancer Brigham and Women's Hospital Dana Farber FDA Gene Therapy Novartis Pharmaceuticals Source Type: news

Gene Therapy, #Yescarta (axicabtagene ciloleucel), Approved for B-Cell Lymphoma
THURSDAY, Oct. 19, 2017 --Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration as the first form of gene therapy for a non-Hodgkin lymphoma (NHL) form of cancer. Diffuse large B-cell lymphoma is the most... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 19, 2017 Category: General Medicine Source Type: news

Gene Therapy, Yescarta (axicabtagene ciloleucel), Approved for B-Cell Lymphoma
THURSDAY, Oct. 19, 2017 --Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration as the first form of gene therapy for a non-Hodgkin lymphoma (NHL) form of cancer. Diffuse large B-cell lymphoma is the most... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 19, 2017 Category: General Medicine Source Type: news

EPA toxicologists classified glyphosate as "possibly carcinogenic to humans" as far back as the 80s; employed Dr. Martin Kuschner to undermine findings in the now infamous "mouse study" they've been manipulating "science" for decades
(Natural News) A 1983 Monsanto study analyzing glyphosate’s effects on rodents could serve as crucial evidence in a lawsuit filed against Monsanto on behalf of plaintiffs who allege exposure to its Roundup herbicide led them to develop non-Hodgkin lymphoma. Environmental Health News reports that attorneys have enlisted the help of an expert pathologist to take... (Source: NaturalNews.com)
Source: NaturalNews.com - October 19, 2017 Category: Consumer Health News Source Type: news

Dana-Farber and Brigham and Women & #39;s researchers laud FDA approval of CAR T-cell therapy for non-Hodgkin Lymphoma
Dana-Farber/Brigham and Women's one of the only centers certified to offer new approach (Source: BWH for Journalists)
Source: BWH for Journalists - October 19, 2017 Category: Research Source Type: news

Dana-Farber and Brigham and Women & #39;s researchers laud FDA approval of CAR T-cell therapy for non-Hodgkin Lymphoma
Dana-Farber/Brigham and Women's one of the only centers certified to offer new approach (Source: BWH News)
Source: BWH News - October 19, 2017 Category: Hospital Management Source Type: news

FDA Okays Another CAR T-Cell Therapy
(MedPage Today) -- First to treat certain types of non-Hodgkin lymphoma (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 18, 2017 Category: American Health Source Type: news

Cutting-edge immunotherapy treatment approved for another deadly cancer
The Food and Drug Administration approved a second version of a groundbreaking treatment Wednesday that genetically alters patients' cells to attack cancer — this time, to fight aggressive non-Hodgkin lymphoma. The treatment is for adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other […]Related:Josh Gordon, new director of the National Institute of Mental Health, weighs its futureA 2-year-old’s kidney transplant was put on hold — after his donor father’s probation violationThe mother jailed for refusing to vaccinate he...
Source: Washington Post: To Your Health - October 18, 2017 Category: Consumer Health News Source Type: news

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 18, 2017 Category: American Health Source Type: news

UChicago Medicine first site in Illinois offering pioneering CAR T-cell therapy for cancer
(University of Chicago Medical Center) The FDA today approved the use of a breakthrough cancer treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin lymphoma. The treatment is a form of CAR T-cell therapy now labelled Yescarta (axicabtagene ciloleucel). The University of Chicago Medicine is the first site in Illinois certified by both Kite Pharma Inc. and Novartis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2017 Category: International Medicine & Public Health Source Type: news

New assay may boost targeted treatment of non-hodgkin lymphoma
(Elsevier) Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40 percent of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype. In a report in The Journal of Molecular Diagnostics, researchers describe their development of a reliable, accessible, rapid, and cost-effective new gene expression signature assay that can enhance lymphoma management by helping to match tumors with the appropriate targeted therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 17, 2017 Category: Biology Source Type: news

Hodgkin's vs. non-Hodgkin's lymphoma: What's the difference?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - October 10, 2017 Category: Consumer Health News Source Type: news

Newer Drug May Prolong Lymphoma Remission
WEDNESDAY, Oct. 4, 2017 -- A newer drug may beat the standard treatment when it comes to battling the blood cancer follicular lymphoma, a clinical trial suggests. Follicular lymphoma is one type of non-Hodgkin lymphoma, a group of cancers that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 4, 2017 Category: General Medicine Source Type: news

NICE recommends use of Janssen ’s Imbruvica for Waldenstr ö m ’s macroglobulinaemia
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Janssen Pharmaceutical ’s Imbruvica (ibrutinib) on the Cancer Drugs Fund (CDF) to treat adults with a type of   non-Hodgkin lymphoma called Waldenstr ö m ’s m… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Bake-Off ’s Chris Geiger writes moving account of cancer
The Great British Bake Off's latest eliminated contestant was diagnosed with non-Hodgkin lymphoma at just 24 years old after doctors dismissed his breathlessness as stress for eight months. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2017 Category: Consumer Health News Source Type: news

Gene Tx Approved for Certain Types of B - Cell Lymphoma
First such treatment for certain types of non - Hodgkin lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 1, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Chi-Med begins Phase I trial of lymphoma drug in China
Hutchison China MediTech (Chi-Med) has begun a Phase I clinical trial of its therapeutic candidate HMPL-689 to treat patients with non-Hodgkin lymphoma in China. (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Gazyva in previously untreated follicular lymphoma
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva® (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin lymphoma, is incurable and characterized by cycles of remission and relapse. (Source: Roche Investor Update)
Source: Roche Investor Update - August 28, 2017 Category: Pharmaceuticals Source Type: news

Significant Portion of Pediatric NHL Cases Occur in Transplant Recipients
Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States. (Source: CancerNetwork)
Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Women having children over 30 give them higher cancer risk
Parents over 35 are linked to an increased risk of leukaemia diagnoses, a Los Angeles study has found. This age group are also linked with higher rates of non-Hodgkin lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 2, 2017 Category: Consumer Health News Source Type: news

US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
THE WOODLANDS, Texas and CAMBRIDGE, Mass. (August 1, 2017)  - Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of independent, community-based oncology practices dedicated to ad... (Source: McKesson News)
Source: McKesson News - August 1, 2017 Category: Information Technology Source Type: news

Nigeria: Nigerian Doctor, Donald Nwosu Battles Deadly Cancer
[This Day] As public health physician, Donald Nwosu battles a rare type of cancer, Non-Hodgkins Lymphoma, Martins Ifijeh chronicles his fight to overcome the deadly disease, adding that he urgently needs help in order to survive it (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 20, 2017 Category: African Health Source Type: news

Monsanto Denies Glyphosate Exposure Could Have Caused Man's Cancer
SAN FRANCISCO - Monsanto Co. on June 16 filed its answer to one of the complaints in the multidistrict litigation for Roundup products, in which it denied that exposure to its product, which contains glyphosate, could have caused the plaintiff's alleged non-Hodgkin lymphoma (NHL) (In re: Roundup Products Liability Litigation, No. 2741 MDL, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 6, 2017 Category: Medical Law Source Type: news

Roche ’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - June 30, 2017 Category: Pharmaceuticals Source Type: news

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news

Loan Woll who had stillborn learns she has stage 4 cancer
Loan Woll, 31, gave birth to her stillborn son Finnick in Ontario, Canada, on January 14. She was told her stage 4 non-Hodgkin lymphoma cancer had caused the death of her child. (Source: the Mail online | Health)
Source: the Mail online | Health - June 27, 2017 Category: Consumer Health News Source Type: news

Monsanto Spin Doctors Target Cancer Scientist In Flawed Reuters Story
In a well-orchestrated and highly coordinated media coup, Monsanto Co. and friends this week dropped a bombshell on opponents who are seeking to prove that the company’s beloved Roundup herbicide causes cancer. A widely circulated story published June 14 in the global news outlet Reuters (for which I formerly worked) laid out what appeared to be a scandalous story of hidden information and a secretive scientist, “exclusive” revelations that the story said could have altered a critical 2015 classification that associated Monsanto’s Roundup to cancer and triggered waves of lawsuits against Monsanto. ...
Source: Science - The Huffington Post - June 16, 2017 Category: Science Source Type: news

FDA accepts priority review for Kite Pharma ’s refractory aggressive NHL treatment
The US Food and Drug Administration (FDA) has accepted priority review for cell therapy company Kite Pharma ’s biologics licence application (BLA) for axicabtagene ciloleucel to treat patients with refractory aggressive non-Hodgkin lymphoma (NHL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 29, 2017 Category: Pharmaceuticals Source Type: news

What You Need to Know if You Have Breast Implants
There is no need to remove implants if you have no problems, but if you have swelling, fluid buildup, lumps or asymmetry you should see a doctor. (Source: NYT Health)
Source: NYT Health - May 14, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Non-Hodgkin's Lymphoma Surgery and Surgeons Source Type: news

A Shocking Diagnosis: Breast Implants ‘ Gave Me Cancer ’
A rare cancer of the immune system, linked to implants, has had devastating effects on women, many of whom had reconstructive surgery after breast cancer. (Source: NYT Health)
Source: NYT Health - May 14, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Allergan Inc Immune System Surgery and Surgeons Cancer Non-Hodgkin's Lymphoma Breasts Plastic Surgery Source Type: news

Man: Case Against Monsanto Should Not Be Stayed Pending Ruling On MDL Transfer
ST. LOUIS - A Missouri man who sued Monsanto Co. for allegedly causing his non-Hodgkin lymphoma (NHL) through the manufacturing and distribution of glyphosate, the active ingredient in Roundup, on April 25 filed a brief in Missouri federal court arguing that the district court should reconsider the stay it issued pending a determination on transfer to the multidistrict litigation because the case does not need to be transferred (Steve Salvaggio, et al. v. Monsanto Company, et al., No. 17-1113, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 2, 2017 Category: Medical Law Source Type: news

Gov. Larry Hogan on Maryland's life sciences cluster: 'This mission is a very personal one to me'
When Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn ’t help but take the moment to remember his own brush with their work. In 2015, the then-new governor was diagnosed with non-Hodgkin's lymphoma. More than a year and a half since reaching remission, he is still cancer free, he told the BioHealth Capital Region forum. The two-day conference at Me dImmune's headquarters in Gaithersburg was held to promote collaboration… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 20, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

Gov. Larry Hogan on Maryland's life sciences cluster: 'This mission is a very personal one to me'
When Maryland Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn ’t help but take the moment to remember his own brush with their work. In 2015, the then-new governor was diagnosed with non-Hodgkin's lymphoma. More than a year and a half since reaching remission, he is still cancer free, he told the BioHealth Capital Region forum. The two-day conference at Me dImmune's headquarters in Gaithersburg was held to promote… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 19, 2017 Category: American Health Authors: Tina Reed Source Type: news

Gov. Larry Hogan on Maryland's life sciences cluster: 'This mission is a very personal one to me'
When Maryland Gov. Larry Hogan stepped up to address a crowd of more than 1,000 life sciences executives and entrepreneurs on Wednesday, he couldn ’t help but take the moment to remember his own brush with their work. In 2015, the then-new governor was diagnosed with non-Hodgkin's lymphoma. More than a year and a half since reaching remission, he is still cancer free, he told the BioHealth Capital Region forum. The two-day conference at Me dImmune's headquarters in Gaithersburg was held to promote… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 19, 2017 Category: Biotechnology Authors: Tina Reed Source Type: news

Judge Remands PCB Case Against Monsanto, Says Removal Was Improper
ST. LOUIS - A federal magistrate judge in Missouri on April 10 remanded a lawsuit brought by residents who contend that polychlorinated biphenyls (PCBs) manufactured by Monsanto Co. are liable for their development of non-Hodgkin lymphoma (NHL) on grounds that it was improperly removed to federal court (Kent N. Burford v. Monsanto Co., et al., No. 16-536, E.D. Mo.; 2017 U.S. Dist. LEXIS 54293). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - April 18, 2017 Category: Medical Law Source Type: news

CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma
This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 7, 2017 Category: Cancer & Oncology Authors: Frederick Locke, MD Tags: Conferences/AACR 2017 Videos Hematologic Malignancies Source Type: news

Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma
This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2017 Category: Cancer & Oncology Authors: Martin Dreyling, MD Tags: Videos Hematologic Malignancies Source Type: news

Moms Exposed To Monsanto Weed Killer Means Bad Outcomes For Babies
Concerns about the world’s most widely used herbicide are taking a new twist as researchers unveil data that indicates pervasive use of Monsanto Co.’s weed killer could be linked to pregnancy problems. Researchers looking at exposure to the herbicide known as glyphosate, the key ingredient in Monsanto’s Roundup-branded herbicides, said they tested and tracked 69 expectant mothers and found that the presence of glyphosate levels in their bodily fluids correlated with unfavorable birth outcomes. The research is still in preliminary stages and the sample size is small, but the team is scheduled to present th...
Source: Healthy Living - The Huffington Post - April 4, 2017 Category: Consumer Health News Source Type: news

Monsanto Denies That Exposure To Glyphosate Causes Cancer
ST. LOUIS - Monsanto Co. on March 28 filed an answer in Missouri federal court denying that any exposure to its herbicide Roundup, with its active ingredient glyphosate, can cause non-Hodgkin lymphoma (NHL) or other cancers, as alleged by numerous individuals who have used Roundup (Steve Salvaggio, et al. v. Monsanto Company, et al., No. 17-1113, E.D. Mo.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - April 4, 2017 Category: Medical Law Source Type: news